A Director at Antares Pharma (NASDAQ: ATRS) is Buying Shares

By George MacDonald

Today, a Director at Antares Pharma (NASDAQ: ATRS), Marvin Samson, bought shares of ATRS for $36k.

Marvin Samson increased his holding by 94.74%. In addition to Marvin Samson, 5 other ATRS executives reported Buy trades in the last month.

Based on Antares Pharma`s latest earnings report from December 31, the company posted quarterly revenue of $11.8M and GAAP net loss of $6.63M. In comparison, last year the company earned revenue of $8.4M and had a GAAP net loss of $10.07M. The company has a one year high of $3.04 and a one year low of $0.67. Currently, Antares Pharma has an average volume of 1.65M.

Starting in March 2013, ATRS received 39 Buy ratings in a row. Six different firms, including Oppenheimer and JMP Securities, currently also have a Buy rating on the stock.

Looking at blogger coverage of ATRS, there is a 57% Bullish tendency on the stock, in relation to a 75% average bullish tendency within the Healthcare sector.

Over the last 3 months, the insider sentiment on Antares Pharma has been positive based on 26 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.

Antares Pharma Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies including novel, pressure-assisted injectors.